That Grp94 in complexes with IgG was the soluble tumor antigen in cancer patients was further confirmed by an enzyme-linked immune assay specifically developed to address the need to measure Grp94-IgG complexes in human plasma as diagnostic and prognostic biomarker. This evidence concerns the gene HSP90B1 and neoplasm.